Marisa Wexler, MS, senior science writer —

A Phase 1 trial testing Annexon Biosciences’ oral treatment candidate ANX1502 — for complement-mediated autoimmune disorders such as cold agglutinin disease (CAD) — in healthy volunteers has moved to its multiple-dosing phase. The company is planning to launch a proof-of-concept study of ANX1502 in people with CAD later…

Note: This story was updated Jan. 30, 2023,  to correct that the CARDINAL trial did not include a placebo group. The U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Enjaymo (sutimlimab-jome) to include cold agglutinin disease (CAD) patients without a history of…

Special considerations should be taken when preparing a blood transfusion for someone with cold agglutinin disease (CAD), a recent study indicates. The study, “Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies,” was published…

People with cold agglutinin disease (CAD) reported clinically significant improvements in health-related quality of life after treatment with Enjaymo (sutimlimab-jome), according to a new analysis of data from the Phase 3 CADENZA clinical trial. These findings “further augment the primary efficacy outcomes of the placebo-controlled Phase 3 CADENZA…

Even with treatment, many people with cold agglutinin disease (CAD) continue to experience moderate or severe anemia and hemolysis events caused by red blood cell destruction, a new analysis found. “Despite high proportions of patients receiving CAD-related therapies during the first year following diagnosis, the number of moderate/severe anemia…

Global Genes and RARE-X, two nonprofit organizations dedicated to improving the lives of people with rare diseases like cold agglutinin disease (CAD), announced they are joining forces, with the merger expected to close by the end of this year. “What was apparent to all of us was how closely…

Although extremely rare, there have been cases of cold agglutinin disease (CAD) and related conditions following vaccination against COVID-19, a recent review study reported. While it’s difficult to draw firm conclusions about cause and effect, scientists say developing CAD may be a very rare side effect from COVID-19 vaccines.

VV-ECMO, a technique used to deliver oxygen to the body when the lungs are not working properly, can be used in people with cold agglutinin disease (CAD) without notable complications, a case report shows. The report, “Veno-venous extra-corporeal membrane oxygenation in a COVID-19 patient with cold-agglutinin haemolytic anaemia:…

A committee of the European Medicines Agency has recommended Enjaymo (sutimlimab-jome) be approved for hemolytic anemia, or anemia due to the destruction of red blood cells, in adults with cold agglutinin disease (CAD). The positive opinion from the agency’s Committee for Medicinal Products for Human Use now will…

Enjaymo (sutimlimab-jome) eased anemia, and reduced fatigue and the need for blood transfusions and other treatments in people with cold agglutinin disease (CAD) who hadn’t received blood transfusions recently, final results from the Phase 3 CADENZA trial show. Results were detailed in the study, “Sutimlimab in patients…